Helius Medical Technologies, Inc. to Participate in the Annual World Congress of the Society for Brain Mapping and Therapeutics

Rhea-AI Summary

Helius Medical Technologies has announced its participation in the Annual World Congress of the Society for Brain Mapping and Therapeutics from July 8-11, 2021, in Los Angeles. The company will receive the Pioneer in Technology Award, recognizing its innovative contributions to neurotechnology. Co-Founder Dr. Jonathan Sackier will present on the PoNS™ device, highlighting its role in treating gait deficits associated with conditions like multiple sclerosis. This non-surgical device delivers electrical stimulation through the tongue, showing promise in enhancing neurological wellness.

Company Selected to Receive the “Pioneer in Technology Award”

NEWTOWN, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced it will participate in the Annual World Congress of the Society for Brain Mapping and Therapeutics, which will be held from July 8-11^th in Los Angeles, California.

The Company has been selected to receive the Pioneer in Technology Award during the event, an award presented by the Society to trail blazing companies who have facilitated the development of pioneering technologies through interdisciplinary approaches that have impacted diagnostics, treatment and healthcare delivery in unprecedented ways.

Dr. Jonathan Sackier, Helius’ Co-Founder and Medical Advisor, will host a presentation during the event titled: From porpoise to PoNS™: the bridge of Varolio and translingual neuromodulation to address balance and gait symptoms. The presentation will include a discussion of the history of neuromodulation, the science behind Helius’ PoNS technology, data from trials in experimental and clinical settings – including trials focused on multiple sclerosis, traumatic brain injury, stroke and cerebral palsy – and the PoNS device’s recent regulatory clearances. The presentation will be held on July 11^th at 10 a.m. Pacific Time.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS^TM). For more information, visit www.heliusmedical.com.

About the PoNS™ Device and PoNS Treatment™

The Portable Neuromodulation Stimulator (PoNS^TM) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy. PoNS is an investigational medical device in the European Union (“EU”) and Australia (“AUS”). It is currently under premarket review by the AUS Therapeutic Goods Administration.

Cautionary Disclaimer Statement: 

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “continue,” “looking ahead,” “will,” “committed to,” “goal,” “expect,” “remain,” “hope” and similar expressions. Such forward-looking statements include, among others, statements regarding the Company’s future strategic and operational execution, the next phase of the Company’s market development activities, clinical and regulatory development plans for the PoNS device, and the timing and success of the Company’s commercialization efforts in the United States.

These statements involve substantial known and unknown risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties regarding the Company’s capital requirements to achieve its business objectives, the impact of the COVID-19 pandemic, the Company’s ability to train physical therapists in the supervision of the use of the PoNS Treatment, the Company’s ability to secure contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, market awareness of the PoNS device, future clinical trials and the clinical development process, manufacturing and supply chain risks, potential changes to the MCIT program, the product development process and FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

FAQ

What award did Helius Medical Technologies receive on July 7, 2021?

Helius Medical Technologies received the 'Pioneer in Technology Award' during the Annual World Congress of the Society for Brain Mapping and Therapeutics.

When is Helius Medical Technologies' presentation at the World Congress?

The presentation by Dr. Jonathan Sackier will take place on July 11, 2021, at 10 a.m. Pacific Time.

What is the PoNS™ device developed by Helius Medical Technologies?

The PoNS™ device is a non-surgical treatment tool designed to assist in gait deficits due to conditions like multiple sclerosis.

Where can I find more information about Helius Medical Technologies?

For more information, visit Helius Medical Technologies' official website at www.heliusmedical.com.

What conditions does the PoNS™ device target?

The PoNS™ device targets gait deficits associated with multiple sclerosis, traumatic brain injury, stroke, and cerebral palsy.